Metallo-β-Lactamases and Aptamer-Based Inhibition

An evolution of antibiotic-resistant bacteria has resulted in the need for new antibiotics. β-Lactam based drugs are the most predominantly prescribed antibiotics to combat bacterial infections; however, production of β-lactamases, which catalyze the hydrolysis of the β-lactam bond of this class of...

Full description

Saved in:
Bibliographic Details
Main Authors: Sung-Kun Kim (Author), Taylor O. Foster (Author), Mieke J. Lahousse (Author), Sara R. Schlesinger (Author)
Format: Book
Published: MDPI AG, 2011-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_fb3cdb6b64c84d779cc7061b4ce3541d
042 |a dc 
100 1 0 |a Sung-Kun Kim  |e author 
700 1 0 |a Taylor O. Foster  |e author 
700 1 0 |a Mieke J. Lahousse  |e author 
700 1 0 |a Sara R. Schlesinger  |e author 
245 0 0 |a Metallo-β-Lactamases and Aptamer-Based Inhibition 
260 |b MDPI AG,   |c 2011-02-01T00:00:00Z. 
500 |a 10.3390/ph4020419 
500 |a 1424-8247 
520 |a An evolution of antibiotic-resistant bacteria has resulted in the need for new antibiotics. β-Lactam based drugs are the most predominantly prescribed antibiotics to combat bacterial infections; however, production of β-lactamases, which catalyze the hydrolysis of the β-lactam bond of this class of antibiotics, by pathogenic bacteria such as Bacillus cereus, are rendering them useless. Some inhibitors of β-lactamases have been found, but there are no inhibitors against a class of β-lactamases known as metallo-β-lactamases, and it has been reported that the number of bacteria that produce metallo-β-lactamases is on the rise. Finding inhibitors of metallo-β-lactamases is thus an urgent necessity. One way to approach the problem is by employing the combinatorial method SELEX. The SELEX method is significant in discovering and producing new classes of inhibitors, as well as providing insight into the development of these inhibitors and paves the way for future aptamer applications that further novel drug discovery. 
546 |a EN 
690 |a metallo-β-lactamase 
690 |a aptamer 
690 |a SELEX 
690 |a inhibitor 
690 |a Bacillus cereus 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 4, Iss 2, Pp 419-428 (2011) 
787 0 |n http://www.mdpi.com/1424-8247/4/2/419/ 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/fb3cdb6b64c84d779cc7061b4ce3541d  |z Connect to this object online.